Mechanismen der subklinischen Inflammation in der Entstehung des Typ-2-Diabetes

C. Herder

doi:10.1055/s-0033-1350375

Diabetologie und Stoffwechsel, Table of Contents

Diabetologie und Stoffwechsel 2013; 8(4): 286-288
DOI: 10.1055/s-0033-1350375

Editorial

Mechanismen der subklinischen Inflammation in der Entstehung des Typ-2-Diabetes

Mechanisms of Subclinical Inflammation in the Development of Type 2 Diabetes

C. Herder

¹Institut für Klinische Diabetologie, Deutsches Diabetes-Zentrum, Leibniz-Zentrum für Diabetesforschung an der Heinrich-Heine-Universität Düsseldorf

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Kolb H, Mandrup-Poulsen T. The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia 2010; 53: 10-20
2 Pickup JC, Crook MA. Is type II diabetes a disease of the innate immune system?. Diabetologia 1998; 41: 1241-1248
3 Herder C, Baumert J, Thorand B et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984–2002. Diabetologia 2006; 49: 921-929
4 Herder C, Klopp N, Baumert J et al. Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984–2002. Diabetologia 2008; 51: 276-284
5 Herder C, Carstensen M, Ouwens DM. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes Metab 2013; 15 (Suppl. 3), (in press)
6 Carstensen M, Herder C, Kivimäki M et al. Accelerated increase in serum interleukin-1 receptor antagonist (IL-1Ra) starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010; 59: 1222-1227
7 Herder C, Peltonen M, Koenig W et al. Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study. Diabetologia 2009; 52: 433-442
8 Kempf K, Herder C, Erlund I et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr 2010; 91: 950-957
9 Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107
10 Ridker PM, Thuren T, Zalewski A et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162: 597-605